| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
INBX Stock Overview
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates.
Inhibrx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.60 |
| 52 Week High | US$47.90 |
| 52 Week Low | US$7.67 |
| Beta | 0 |
| 1 Month Change | 48.15% |
| 3 Month Change | 61.87% |
| 1 Year Change | -24.21% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 14.40% |
Recent News & Updates
Inhibrx: Potential To Move To Registration Study With INBRX-101
Positive results have been released thus far from a phase 1 study using INBRX-101 for the treatment of patients with Alpha-1 Antitrypsin Deficiency. It is expected that the Alpha-1 Antitrypsin Deficiency Augmentation therapy market could reach $1.95 billion by 2026. If FDA gives green light to Inhibrx, then it should be able to initiate a pivotal registration study using INBRX-101 for patients with Alpha-1 Antitrypsin Deficiency 2nd half of 2022. INBRX-109, INBRX-106, INBRX-105, and INBRX-121 are 4 additional drugs in the pipeline being advanced as treatments for cancer; All 4 of these drugs plus INBRX-101 utilize the company's Single-domain antibody technology platform.
Shareholder Returns
| INBX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 28.6% | 6.3% | 0.3% |
| 1Y | -24.2% | -25.9% | -13.5% |
Return vs Industry: INBX exceeded the US Biotechs industry which returned -25.9% over the past year.
Return vs Market: INBX underperformed the US Market which returned -13.5% over the past year.
Price Volatility
| INBX volatility | |
|---|---|
| INBX Average Weekly Movement | 17.0% |
| Biotechs Industry Average Movement | 12.8% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: INBX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: INBX's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 109 | Mark Lappe | https://inhibrx.com |
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company’s therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications.
Inhibrx, Inc. Fundamentals Summary
| INBX fundamental statistics | |
|---|---|
| Market Cap | US$921.76m |
| Earnings (TTM) | -US$110.75m |
| Revenue (TTM) | US$7.03m |
131.2x
P/S Ratio-8.3x
P/E RatioIs INBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INBX income statement (TTM) | |
|---|---|
| Revenue | US$7.03m |
| Cost of Revenue | US$91.90m |
| Gross Profit | -US$84.87m |
| Other Expenses | US$25.88m |
| Earnings | -US$110.75m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.84 |
| Gross Margin | -1,207.64% |
| Net Profit Margin | -1,575.91% |
| Debt/Equity Ratio | -3,449.8% |
How did INBX perform over the long term?
See historical performance and comparison